View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 12, 2011

Biopharmaceuticals Should Feature in Trade Discussions, Says Eli Lilly CEO

Eli Lilly chairman, president and CEO John Lechleiter has claimed that biopharmaceuticals should be included in transatlantic trade and economic discussions in order to promote innovation. Speaking at the Transatlantic Partnership in the 21st Century conference held in Germany, Lechl

By cms admin

Eli Lilly chairman, president and CEO John Lechleiter has claimed that biopharmaceuticals should be included in transatlantic trade and economic discussions in order to promote innovation.

Speaking at the Transatlantic Partnership in the 21st Century conference held in Germany, Lechleiter said that biopharmaceutical innovation can pose substantial benefits to the global economy.

“New medicines are one of the most cost-effective investments we can make to improve health care and enable more efficient use of health care budgets,” said Lechleiter.

“We must ensure that health care reform in our countries will help promote biopharmaceutical innovation and not undermine it.”

Lechleiter continued to claim that short-term cost pressures enforced by governments are triggering responses that are hampering the sector, and called for consistent regulatory policies and intellectual property proportion to maintain medical innovation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology